Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$9.63B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  GMDA
Gamida Cell Ltd
GMDA
49 / 100
Penny Stock
$0.01arrow_drop_down8.65%-$0.00

Performance History

Stocklytics logo
Key Stats
Open$0.01
Prev. Close$0.01
EPS-0.82
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap4337295.00
PE Ratio-
LOWHIGH
Day Range0.01
0.01
52 Week Range0.00
2.51
Ratios
P/B Ratio117.40
Revenue$1.78M
Operating M. %-2,680.24%
Earnings$0.00
Earnings Growth %20.63%
EBITDA Margin %-1,000.00%
ROE %-1,103.79%
EPS-0.82

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

49vs 54. Market Avg.

All Score 49 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

GMDAMARKET
Value5540
Quality3040
Ownership1617
Growth5347
Dividends-38
check_circle

Gamida Cell Ltd's Price discount from 1 year high of 99.3% is great compared to market average of 19.17%. This indicates GMDA could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$745.69
24H (%)arrow_drop_up1.96%
24H ($)$14.35
MARKET CAP$695.32B
PRICE$486.17
24H (%)arrow_drop_down1.02%
24H ($)-$5.05
MARKET CAP$452.88B
PRICE$149.56
24H (%)arrow_drop_up0.29%
24H ($)$0.44
MARKET CAP$359.34B
PRICE$126.88
24H (%)arrow_drop_down0.04%
24H ($)-$0.06
MARKET CAP$321.54B

About Gamida Cell Ltd (GMDA)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Abigail L. Jenkins
Headquarters
Jerusalem
Employees
143
Exchange
NASDAQ
add Gamida Cell Ltd to watchlist

Keep an eye on Gamida Cell Ltd

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Gamida Cell Ltd's (GMDA) price per share?

The current price per share for Gamida Cell Ltd (GMDA) is $0.02. The stock has seen a price change of -$0 recently, indicating a -8.65% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Gamida Cell Ltd (GMDA)?

For Gamida Cell Ltd (GMDA), the 52-week high is $2.51, which is 16.52K% from the current price. The 52-week low is $0.01, the current price is 88.75% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Gamida Cell Ltd (GMDA) a growth stock?

Gamida Cell Ltd (GMDA) has shown an average price growth of -67.73% over the past three years. It has received a score of -1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Gamida Cell Ltd as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Gamida Cell Ltd (GMDA) stock price performance year to date (YTD)?

As of the latest data, Gamida Cell Ltd (GMDA) has a year-to-date price change of -96.18%. Over the past month, the stock has experienced a price change of -95.53%. Over the last three months, the change has been -95.69%. Over the past six months, the figure is -98.15%. Looking at a longer horizon, the five-year price change stands at -99.83%.

help
Is Gamida Cell Ltd (GMDA) a profitable company?

Gamida Cell Ltd (GMDA) has a net income of -$63M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -2.68K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.78M, although specific revenue growth data is currently not available. Operating income is noted at -$72.64M. Furthermore, the EBITDA is -$75.91M.

help
What is the market capitalization of Gamida Cell Ltd (GMDA)?

Gamida Cell Ltd (GMDA) has a market capitalization of $4.34M. The average daily trading volume is 2.3M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.